Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is well positioned in the diabetes treatment market and has a strong pipeline with potential for growth. The positive results from previous studies and the expected results from the ongoing Phase 3 trial suggest promising revenue potential in the future. Additionally, partnerships and collaborations with other companies highlight the company's expertise and potential for further advancements in the field of chronic disease treatment. On a fundamental level, vTv Therapeutics has the potential for success and is likely to see long-term growth in the market.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company with a focus on developing oral, small-molecule drug candidates for the treatment of chronic diseases, such as diabetes. While the company's pipeline includes multiple drug candidates, the most promising one is cadisegliatin (TTP399), which has shown positive results in clinical trials for the treatment of type 2 diabetes. However, there are still concerns regarding its efficacy and safety profile in type 1 diabetes and the potential regulatory risks involved. The company's current financials and partnerships also present risks to its success. Therefore, the negative outlook on vTv Therapeutics' stock is primarily driven by these fundamental factors.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.